Contineum Therapeutics, Inc. · NASDAQ:CTNM

Contineum Therapeutics, Inc. financial statements

Contineum Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue0050.0M00
Cost of revenue323.0K258.0K195.0K329.0K
Gross profit-323.0K-258.0K50.0M-329.0K
Research and development51.5M38.4M27.6M16.9M22.4M
Selling, general and administrative16.5M12.5M6.32M5.83M6.29M
Operating income-68.1M-50.9M16.1M-22.7M-28.6M
Depreciation and amortization323.0K258.0K195.0K329.0K325.0K
EBITDA-67.7M-50.6M16.3M-22.4M-28.3M
Interest expense0208.0K388.0K332.0K
Income before tax-60.1M-42.3M23.2M-24.3M-29.0M
Income tax00450.0K241.0K
Net income-60.0M-42.3M22.7M-24.3M-29.0M
Earnings per share, basic-2.17-2.181.36-0.97-1.15
Earnings per share, diluted-2.17-2.180.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents75.6M21.9M15.5M5.57M4.63M
Short-term investments187.3M182.8M109.7M41.7M64.4M
Current assets267.9M206.4M127.7M48.4M69.8M
Property, plant and equipment830.0K989.0K678.0K
Total assets276.6M212.8M130.4M50.6M70.5M
Accounts payable1.02M1.81M635.0K430.0K660.0K
Current liabilities9.74M9.97M5.48M7.55M3.67M
Long-term debt3.66M
Total debt8.25M6.26M193.2M5.85M4.91M
Total liabilities15.7M14.8M5.70M11.4M8.93M
Shareholders' equity261.0M198.1M-67.9M39.3M61.6M
Shares outstanding27.7M25.9M2.35M25.1M25.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-55.3M-32.8M19.3M-20.1M-26.3M
Capital spending-231.0K-514.0K-414.0K-118.0K-168.0K
Free cash flow-55.5M-33.4M18.9M-20.2M-26.4M
Cash from investing-3.71M-69.7M-65.6M22.3M-65.0M
Cash from financing112.7M109.0M56.2M-1.24M79.8M
Share buybacks0-28.0K-4.00K0
Change in cash53.7M6.42M9.96M939.0K-11.4M